Prerpints.org logo
Preprint
Article

The Preventive Effects of Statin on Lung Cancer Development in Patients with Idiopathic Pulmonary Fibrosis Using the National Health Insurance Service Database in Korea

Altmetrics

Downloads

166

Views

40

Comments

0

Submitted:

20 July 2023

Posted:

25 July 2023

You are already at the latest version

Alerts
Abstract
Little is known about the effect of statin use in lung cancer development in idiopathic pulmonary fibrosis (IPF). We analyzed the database of the National Health Insurance Service to further investigate the clinical impacts of statin on lung cancer development and overall survival (OS) in IPF patients. The analysis included 9,182 individuals diagnosed with IPF, of which 3,372 (36.7%) were statin users. Compared to statin non-users, the time from diagnosis of IPF to lung cancer development and OS were longer in statin users in IPF patients. In Cox proportional hazard regression models, higher statin compliance, statin use, and being female had an inverse association with lung cancer risk, while older age at diagnosis of IPF and smoking history were associated with higher risk of lung cancer in IPF patients. For OS, statin use, female sex, higher exercise frequency, and diabetes were associated with longer survival. In contrast, older age at diagnosis of IPF and smoking history were associated with shorter OS in IPF patients. These data from a large population indicate that statin had an independent protective association with lung cancer development and mortality in IPF patients.
Keywords: 
Subject: Medicine and Pharmacology  -   Internal Medicine

1. Introduction

Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors that competitively block the active sites of lipid-lowering enzymes [1]. The main therapeutic effect is inhibition of cholesterol biosynthesis. However, other diverse actions called “pleiotropy” were reported, including improvement of cardiovascular function [2], anti-inflammatory effects [3], and anti-fibrotic effects [4,5].
Some studies have indicated that statins exert anticancer effects by inducing apoptosis and inhibiting tumor cell growth and angiogenesis [6,7,8]. Recent research suggests antitumor effects of statin [9,10,11,12] and its synergistic potency in chemo-resistant lung cancer populations [13,14,15,16].
Clinically, statin is associated with reduced all-cause mortality in interstitial lung disease and idiopathic pulmonary fibrosis (IPF) [17,18]. Also, statin attenuates decline in lung function in the elderly [19]. Lung cancer is a common complication of IPF [20,21], with an incidence of approximately 22.9 per 10,000 person-years, which is approximately five times that in the general population. Kim et al. published a study showing that IPF patients with lung cancer had poor 5-year survival rates compared to non-IPF patients (14.5% vs. 30.1%; p < 0.001) [22]. Moreover, there was higher tendency of treatment-related adverse events [23] such as postoperative clinical deterioration, acute exacerbation (AE), and radiation pneumonitis [24,25,26] among IPF patients with lung cancer. Therefore, the importance of lung cancer prevention in IPF patients is very high.
To date, few studies have examined the role of statins in the risk of lung cancer development among IPF patients in large-scale cohorts. We analyzed the database of the National Health Insurance Service (NHIS) in Republic of Korea to further investigate the clinical impacts of consecutive statin use on lung cancer development and OS in IPF patients.

2. Materials and Methods

2.1. Study database

This study collected data from NHIS, which is based on a nationwide social security system with more than 50 years of history in Korea. Nearly all Korean citizens (97.2%, ~ 50 million) are enrolled in the NHIS, and data of the study population include demographics, medical treatment, and disease diagnosis according to the International Classification of Diseases, 10th Revision (ICD-10) [27]. The NHIS dataset includes all inpatient and outpatient medical claims and the corresponding codes for diagnoses and treatment procedures [28].
We collected and retrospectively reviewed IPF patients among adults older than 40 years during the study period between 2002 and 2018 with a two-year washout period; the patients diagnosed with IPF from 2002 to 2004 were excluded. Among IPF patients older than 40, we grouped them based on more than two visits to an outpatient clinic per year.
IPF was defined as J841 or J848, and patients with possible interstitial lung diseases or other systemic involvement with lung disease codes were excluded as follows: M05.1, M05.2, M05.3, M05.8, M05.9, M06.0, M06.8, M06.9, M30.1, M31.3, M31.7, M32, M33, M34, M35.0, M35.1, D86, J84.0, J60~J70.9. Code J84 was classified as a rare intractable disease category in Korea. The government supports these patients with medical cost reduction of up to 10% of the total cost; therefore, the ICD for this disease indicates IPF patients retained in the database [29]. Lung cancer was defined as C33 or C34. To validate latent factors that would affect lung cancer development, we excluded those who had a history of cancer or were newly diagnosed before diagnosis of IPF. We also excluded those who were diagnosed with lung cancer less than one year before clinically proven IPF diagnosis during the washout period.

2.2. Endpoints and study outcomes

The primary endpoint of this study was the development of lung cancer in IPF patients according to statin use during the study period. This was calculated by subtracting the date of first IPF diagnosis from first lung cancer diagnosis. The secondary endpoint was the OS of IPF patients according to statin use. OS was the duration from the day of first IPF diagnosis to death or the study end date.

2.3. Statin use

We defined a regular statin user as a patient who had been prescribed statin consecutively at least four weeks (28 days) after the diagnosis of IPF. If the interval between prescriptions was less than two weeks, the patient was included in the regular statin group. The study did not include any patients prescribed statin before diagnosis of IPF to exclude conditional bias of statin use. Drug compliance was estimated as the ratio of total dates of prescription to the study period.

2.4. Statistical analysis

The paired t-test was used for continuous data, and the chi-square test was used for categorical data to generate descriptive tables. Survival was analyzed using a Kaplan–Meier plot and the log-rank test. Kaplan-Meier analysis was used to visualize the duration between lung cancer diagnosis and death according to statin use. Log rank test was used to validate the significant difference of time-to-event between statin and non-statin user groups. Cox proportional hazard regression analysis was used to adjust for multiple variables affecting the hazard of lung cancer development with a 95% confidence interval (CI). All P-values were two-tailed, with statistical significance set to p < 0.05. All statistical analyses were performed using SAS Version 7.1 (SAS Institute, Inc., Cary, NC, USA) and R Version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

The final analysis included 9,182 individuals diagnosed with IPF, of which 3,372 (36.7%) were statin users. The baseline characteristics of study patients are listed in Table 1. The age at first diagnosis of IPF was younger in the statin user group (67.2 ± 11.2 vs. 64.0 ± 10.2, p < 0.001). The proportion of males was higher in the statin non-user group (67.1% vs. 59.4%, p < 0.001). Mean body mass index (BMI) (23.0 ± 3.2 vs. 24.0 ± 3.1, p < 0.001), total cholesterol (184.2 ± 34.8 vs. 199.7 ± 42.6, p < 0.0001), and systolic (125.2 ± 17.1 vs. 126.6 ± 16.8, p < 0.0001) and diastolic blood pressure (76.3 ± 10.6 vs. 77.3 ± 10.8, p < 0.0001) were higher in the statin user group. Smoking history as never, ex-, or current was not statistically different between statin users and statin non-users. However, the statin non-user group showed a higher smoking amount than the statin user group (38.1% vs. 25.7% for less than a half pack, 14.3% vs. 23.3% for a pack to less than two packs, p < 0.001). In terms of drinking habits, the proportion of daily drinking (6.2% vs. 4.6%, p = 0.004) was higher in the statin non-user group, but the amount consumed at a time (50.1% vs. 43% for one to two drinks; 7.2% vs. 12.7% for five to six drinks; 5.7% vs. 7.3% for seven to nine drinks; p = 0.001) was lower. Interestingly, the frequency of no physical activity was higher (63.9% vs. 57.5%, p < 0.0001) and the mean frequency of vigorous (0.8 ± 1.7 vs. 0.9 ± 1.8, p = 0.022) and moderate (1.0 ± 1.9 vs. 1.2 ± 2.0, p = 0.036) physical activity per week were lower in the statin non-user group. The proportion of comorbidities of hypertension (14.7% vs. 18.7, p < 0.0001) and heart disease (3.0% vs. 4.2%, p = 0.026) was higher in the statin user group, but that of cerebrovascular diseases (1.9% vs. 1.0%, p = 0.013) was higher in the statin non-user group.
The clinical outcomes of this study are shown in Table 2. Among 9,182 IPF patients analyzed during the study period, 850 were diagnosed as lung cancer. The incidence of lung cancer was similar in the statin user group and statin non-user group (9.2% vs. 9.4%, p = 0.803) during the study period. However, the duration from the date diagnosed with IPF to the development of lung cancer was significantly longer in the statin group (2,194.6 ± 1601.4 vs. 3,361.0 ± 1331.2, p < 0.001). Comparing the mortality rate between the statin user and non-user groups, OS was longer in the statin users (2413.9 ± 1778.7 vs. 3,741.8 ± 1443.1 days, Log rank p < 0.0001) and total number of deaths was significantly lower in (66.9% vs, 41.6%, hazard ratio [HR] 0.41, 95% CI 0.39–0.44, Log rank p < 0.0001). We obtained cumulative lung cancer incidence curves of stain users and statin non-users based on Kaplan-Meier plot analysis (Figure 1).
In multivariate analysis using a Cox regression model for lung cancer development in IPF patients, higher statin compliance (adjusted HR [aHR] 0.66, 95% CI 0.48–0.90, p < 0.001), statin use (aHR 0.63, 95% CI 0.53–0.76, p < 0.001), and female sex (aHR 0.43, 95% CI 0.33–0.56, p < 0.001) were independently associated with reduced lung cancer development in IPF patients. In contrast, the risk of cancer development increased in the group of patients diagnosed with IPF at an older age (aHR 1.05, 95% CI 1.04–1.06, p < 0.001) and with smoking (aHR 1.55, 95% CI 1.39–1.72, p < 0.001).
Table 3. Cox proportional hazard regression analysis of the clinical variables affecting lung cancer development in IPF patients.
Table 3. Cox proportional hazard regression analysis of the clinical variables affecting lung cancer development in IPF patients.
aHR Lower .95 Upper .95 p-value
Statin compliance 0.6561 0.4807 0.8954 < 0.001
Statin use 0.6329 0.5260 0.7614 < 0.001
Sex – female 0.4311 0.3332 0.5576 < 0.001
Age at first diagnosis of IPF 1.0455 1.0357 1.0554 < 0.001
BMI 1.0057 0.9762 1.0362 0.707
Blood pressure
 Systolic 0.9995 0.9922 1.0069 0.366
 Diastolic 0.9995 0.9880 1.0111 0.934
Smoking history (ex + current) 1.5460 1.3911 1.7183 < 0.001
Alcohol frequency 0.9982 0.9315 1.0696 0.959
Exercise frequency 0.9537 0.8886 1.0235 0.188
Comorbidities
 Liver diseases 1.2332 0.6567 2.3158 0.514
 Hypertension 1.0478 0.8229 1.3342 0.705
 Stroke 1.7280 0.7670 3.8930 0.187
 Heart diseases 1.0514 0.6454 1.7129 0.84
 Diabetes 1.0218 0.7330 1.4246 0.899
 Cancers 0.7224 0.3960 1.3180 0.289
aHR; Adjusted hazard ratio, IPF; Idiopathic pulmonary fibrosis, BMI; Body mass index.
We also analyzed the risk factors for mortality in IPF patients after adjusting for demographic variables using multivariate Cox regression (Table 4). Statin use (aHR 0.43, 95% CI 0.39–0.46, p < 0.001), female sex (aHR 0.67, 95% CI 0.61–0.73, p < 0.001), higher exercise frequency (aHR 0.93, 95% CI 0.90–0.96, p < 0.001), and diabetes (aHR 0.78, 95% CI 0.69–0.88, p < 0.001) were associated with reduced risk of mortality in IPF patients. In contrast, older age at IPF diagnosis (aHR 1.07, 95% CI 1.07–1.08, p < 0.001) and smoking history (aHR 1.06, 95% CI 1.01–1.11, p = 0.0182) were associated significantly with shorter OS in IPF patients.

4. Discussion

We identified clinical impacts of regular consecutive statin use in IPF patients who had both delayed lung cancer and prolonged OS. In Cox proportional hazard regression models, higher statin compliance, statin use, and female sex were independently associated with reduced risk of lung cancer, and older age at diagnosis of IPF and smoking history were associated with higher risk of lung cancer in IPF patients. For OS, statin use, female sex, higher exercise frequency, and diabetes were associated with longer survival. In contrast, older age at diagnosis of IPF and smoking history were associated with shorter OS in IPF patients.
Aside from the well-known lipid-lowering effect, statins were reported to have anti-cancer effects through various pathways including inhibition of inflammation, immunomodulation, and angiogenesis [7]. Recently, the long-term use of statins was reported to reduce the risk of mortality in patients with lung cancer [30]. In a meta-analysis, statin use after diagnosis of lung cancer had a survival benefit for OS (HR 0.68, 95% CI 0.51–0.92) compared to those using statins before diagnosis.[31] Statins were also associated with prolonged survival in non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)s.[32] Furthermore, statins can overcome EGFR-TKI resistance in patients with lung cancer harboring KRAS mutation, and they provided an increased response rate in lung cancer patients previously treated with nivolumab [33,34]. In contrast, there was no significant difference in efficacy between a group with addition of simvastatin to afatinib and a group with afatinib alone in patients with non-adenocarcinomatous NSCLC.[35]
IPF has a progressive clinical course including a decline in pulmonary function, decrease in vital capacity, and diffusing capacity for carbon monoxide (DLCO).[36] Further, lung cancer is a common morbidity of IPF with a prevalence of 4.4% to 13%.[37] If lung cancer develops in IPF patients, treatment modalities are limited regardless of lung cancer stage. The treatment goal for early-stage resectable lung cancer is complete remission. Standard curative treatment for patients with NSCLC is lobectomy.[38] Lung resection including lobectomy can cause a reduction in lung function, acute exacerbation (AE) of IPF, and acute respiratory distress syndrome (ARDS).[39] For patients who are not surgical candidates due to medical reasons (e.g., cardiac or pulmonary failure), stereotactic ablative radiotherapy is a potential treatment option with comparable efficacy to surgery.[40] However, severe pulmonary toxicity such as radiation pneumonitis or ARDS was reported in 1.5–20% of patients who received stereotactic ablative radiotherapy in lung cancer patients with IPF.[41] Drug pneumonitis and IPF AE often recur in the advanced stages of lung cancer in IPF patients.[42,43] In a retrospective study, the incidence of lung cancer was reduced in IPF patients treated with pirfenidone.[44] However, no definite conclusion can be drawn from that retrospective study. For these reasons, strategies for early diagnosis and prevention of lung cancer are needed in IPF patients.
In our study, stain use was associated with delayed time from IPF diagnosis to lung cancer development. In a randomized controlled trial, there was a lower forced vital capacity (FVC) decline in IPF patients who received statins at baseline versus those who did not.[45] Also, statin use attenuated the decline in lung function in the elderly, and the effect of statins was estimated to be beneficial regardless of smoking status even though the size of the improvement varied among smoking groups.[19] In IPF patients, risk factors for lung cancer included being male, current smoking at IPF diagnosis, and rapid annual decline of 10% or more in FVC.[36] Decreased lung function is linked to increased inflammation and oxidative stress, and anti-inflammatory properties of statins were investigated in respiratory disease. In an animal study, statins reduced neutrophil levels in lung tissue damaged by lipopolysaccharides.[46] Also, statins protected against smoking-induced lung damage and showed anti-inflammatory effects on the lung.[47] In lung transplant recipients, the levels of neutrophils and lymphocytes in the bronchoalveolar lavage of statin users were reduced compared with nonusers.[48] The inhibitory effect of statin on Ras farnesylation was well investigated. Kras alleles are activated in human lung adenocarcinomas, and inhibition of this is important in lung cancer prevention.[49] Also, lovastatin inhibits cell proliferation, cell cycle progression, and apoptosis in NSCLC cells through minichromosome maintenance (MCM) 2, involved in G1/S cell cycle inhibition.[50] Inflammation affects many aspects of malignancy including the proliferation and survival of cancer cells, angiogenesis, tumor metastasis, and tumor response to chemotherapeutic drugs.[51] The exact mechanism of the preventive effect of statin on lung cancer development in IPF patients is not fully understood, but it is believed that anti-inflammation actions on fibrotic lungs and the resulting lower decline in lung function may delay the occurrence of lung cancer. However, in meta-analysis, non-significant decrease of total lung cancer risk was observed among all statin users (RR = 0.89, 95% CI 0.78–1.02).[52] Further randomized controlled trials and high quality cohort studies are needed to confirm this association.
In our study, statin users had lower risk of death among IPF patients. This finding is consistent with a previous study. Kreuter et al. reported that statins might have a beneficial effect on the clinical outcomes of IPF patients including lower risks of death, six-minute walk distance decline, all-cause hospitalization, and IPF-related mortality.[18] Repetitive alveolar epithelial injury triggered the early development of IPF. The exact etiology of IPF is unknown, and all stages of fibrosis are accompanied by innate and adaptive immune responses.[53] Modulatory effects of statins on pathways of fibrosis were investigated by in vitro studies. Exposure to statins resulted in a reversible and time-dependent change in cell morphology in human renal fibroblasts.[54] Fluvastatin inhibits TGF-ß1-induced thrombospondin-1 expression in coronary artery smooth muscle cells.[55] However, statin use and all-cause mortality in IPF patients showed controversial results based on a statistical analysis.[56] A prospective cohort study with dosage of statin, statin adherence, and use of concurrent antifibrotics is needed to confirm beneficial effects of statin therapy in IPF patients.
In our study, higher exercise frequency decreased all-cause mortality by 8% in IPF patients. It is well known that cardiopulmonary exercise tests and six-min walk tests provide prognostic value of mortality in patients with IPF. [57] Decreased physical activity was associated with lower progression-free survival (HR 12.1, 95% CI, 1.9–78.8, P = 0.009) in IPF patients. Lower quadriceps strength and higher depression scores contribute to lower physical activity. [58] Pulmonary rehabilitation using exercise training is effective for improving exercise capacity, dyspnea, and quality of life in IPF patients. [59] Also, pulmonary rehabilitation noncompletion and nonresponse were associated independently with increased one-year all-cause mortality in IPF patients. [60] Even without active intervention such as respiratory rehabilitation, life style behaviors such as shorter daily sitting and longer weekly walking were associated with reduced hospitalization and mortality risks in patients with IPF. [61] Although the exercise frequency of our study was collected using a subjective self-report, it supports the previous study findings that exercise can lower the mortality of IPF patients based on large-scale cohort data.
Interestingly, not only did the exercise frequency reduce all-cause mortality, but comorbid diabetes showed a 22% risk reduction of death in IPF patients. The biology of aging may influence the susceptibility to lung fibrosis in the elderly, increasing the incidence of IPF in patients over 60 years of age [62]. Relatively older populations with IPF have variable comorbidities such as hypertension, cardiovascular diseases, and diabetes. Type 2 diabetes mellitus (DM) is a common underlying disease in many IPF patients [63]. DM is a systemic metabolic disease characterized by persistent hyperglycemia, and the lungs are targeted by diabetic micro-vascular damage [64]. Epidemiological research reported that diabetes is a risk factor for IPF, with the prevalence of IPF accompanied by DM estimated to be 10–42% even when excluding cases treated with glucocorticoids [65,66]. Further, DM was reported to be a risk factor with higher mortality in an IPF population (HR 2.5, 95% CI 1.04–5.9) [67]. Contrary to the prior study, our study suggested that DM was associated with reduced risk of mortality in IPF patients. This may be partly due to diabetic medications. Metformin is the first-choice of treatment for glycemic control [68]. Aside from the glucose lowering effect, metformin was involved in anti-fibrotic physiology associated with AMPK activation and showed an inhibitory effect in myofibroblasts differentiation [69]. Also, GLP-1 receptor agonists were found to have anti-pulmonary fibrotic effects and alleviated bleomycin-induced lung damage and fibrosis through inactivation of nuclear factor kappa-B in animal studies. [70] In our study, we did not conduct an investigation of diabetic drugs, so it was not possible to confirm whether mortality was reduced by DM or diabetic drugs. Further investigations through a survey on individualized diabetic medication intake are necessary to determine the effect of DM on mortality in IPF patients.
The limitations of our study should be recognized. First, as the study design was retrospective and based on a large population-based cohort, there is the possibility of selection bias of confounding factors that might have influenced the study results. Second, we tried to include drug compliance, but the true medication adherence could not be estimated. Instead, we performed a mathematical assessment of drug compliance based on the total days of statin prescribed divided by the study period. Third, the dose and the different potency of statin were not included as confounding factors. Also, we did not consider antifibrotics (including pirfenidone and nintedanib) as confounding factors. Lastly, we did not include the severity and status of IPF based on pulmonary function (e.g., FVC, DLCO). To identify further effects of statin use on lung cancer development and mortality in IPF patients, a well-designed large scale prospective study is necessary.

5. Conclusions

The goal of this study was to assess the clinical impact of consecutive statin administration on the development of lung cancer and OS in patients with IPF using the NHIS database. The findings of this study showed that consecutive statin use delayed the onset of lung cancer in IPF patients and improved OS rates. Considering the higher prevalence of comorbidities such as diabetes and hypertension, in IPF patients, addition of statin would be beneficial for clinical outcomes. A well-designed large-scale cohort study is needed to confirm the beneficial effects of statin use on preventing lung cancer development and reduced risk of mortality in IPF patients.

Author Contributions

Conceptualization, H.S.K. and Y.J.L.; Data curation, H.S.K., N.Y.K., J.W.R., and Y.J.L.; Formal analysis, H.S.K. and N.Y.K.; Funding acquisition, H.S.K.; Investigation, H.S.K., N.Y.K., Y.H.K., and Y.J.L.; Methodology, H.S.K. and N.Y.K.; Project administration, H.S.K., Y.H.K., and Y.J.L.; Resources, H.S.K. and N.Y.K.; Software, N.Y.K.; Supervision, H.S.K., S.S.K., and Y.H.K.; Validation, H.S.K., N.Y.K., J.H.N., and Y.H.K.; Visualization, N.Y.K..; Writing—original draft, H.S.K., E.G.L., Y.J.L., J.W.R., and Y.H.K.; Writing—review and editing, H.S.K., Y.J.L, S.S.K., and Y.H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund, 2020 (BCMC20BD07).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of The Catholic University of Korea (IRB no: HC20ZISI0006)

Informed Consent Statement

Informed consent was waived because data analysis was performed retrospectively using anonymized data derived from the NHIS in Korea.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: NHIS sharing service websites (http://nhiss.nhis.or.kr, accessed on 15 April 2022).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Morofuji, Y.; Nakagawa, S.; Ujifuku, K.; Fujimoto, T.; Otsuka, K.; Niwa, M.; Tsutsumi, K. Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals 2022, 15, 151. [Google Scholar] [CrossRef] [PubMed]
  2. Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109, Iii39–Iii43. [Google Scholar] [CrossRef] [PubMed]
  3. Jain, M.K.; Ridker, P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005, 4, 977–987. [Google Scholar] [CrossRef]
  4. Schaafsma, D.; McNeill, K.D.; Mutawe, M.M.; Ghavami, S.; Unruh, H.; Jacques, E.; Laviolette, M.; Chakir, J.; Halayko, A.J. Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts. Respir Res 2011, 12, 113. [Google Scholar] [CrossRef]
  5. Schaafsma, D.; Dueck, G.; Ghavami, S.; Kroeker, A.; Mutawe, M.M.; Hauff, K.; Xu, F.Y.; McNeill, K.D.; Unruh, H.; Hatch, G.M. , et al. The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle. Am J Respir Cell Mol Biol 2011, 44, 394–403. [Google Scholar] [CrossRef]
  6. Li, F.; Liu, G.; Roudi, R.; Huang, Q.; Swierzy, M.; Ismail, M.; Zhao, S.; Rueckert, J.C. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. BMJ Open 2018, 8, e022161. [Google Scholar] [CrossRef]
  7. Vallianou, N.G.; Kostantinou, A.; Kougias, M.; Kazazis, C. Statins and cancer. Anticancer Agents Med Chem 2014, 14, 706–712. [Google Scholar] [CrossRef]
  8. Mantha, A.J.; Hanson, J.E.; Goss, G.; Lagarde, A.E.; Lorimer, I.A.; Dimitroulakos, J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005, 11, 2398–2407. [Google Scholar] [CrossRef]
  9. Luttman, J.H.; Hoj, J.P.; Lin, K.H.; Lin, J.; Gu, J.J.; Rouse, C.; Nichols, A.G.; MacIver, N.J.; Wood, K.C.; Pendergast, A.M. ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Cell Rep 2021, 37, 109880. [Google Scholar] [CrossRef]
  10. Fernández, L.P.; Merino, M.; Colmenarejo, G.; Moreno-Rubio, J.; Sánchez-Martínez, R.; Quijada-Freire, A.; Gómez de Cedrón, M.; Reglero, G.; Casado, E.; Sereno, M. , et al. Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non-small cell lung cancer. Mol Oncol 2020, 14, 3135–3152. [Google Scholar] [CrossRef]
  11. Young, R.P.; Hopkins, R.J. The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention. Curr Mol Pharmacol 2017, 10, 46–59. [Google Scholar] [CrossRef] [PubMed]
  12. Nam, G.H.; Kwon, M.; Jung, H.; Ko, E.; Kim, S.A.; Choi, Y.; Song, S.J.; Kim, S.; Lee, Y.; Kim, G.B. , et al. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. J Immunother Cancer 2021, 9. [Google Scholar]
  13. Otahal, A.; Aydemir, D.; Tomasich, E.; Minichsdorfer, C. Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines. Sci Rep 2020, 10, 959. [Google Scholar] [CrossRef]
  14. Takada, K.; Shimokawa, M.; Takamori, S.; Shimamatsu, S.; Hirai, F.; Tagawa, T.; Okamoto, T.; Hamatake, M.; Tsuchiya-Kawano, Y.; Otsubo, K. , et al. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer 2022, 22, 503. [Google Scholar] [CrossRef] [PubMed]
  15. Rossi, A.; Filetti, M.; Taurelli Salimbeni, B.; Piras, M.; Rizzo, F.; Giusti, R.; Marchetti, P. Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC. Cancer Rep (Hoboken) 2021, 4, e1368. [Google Scholar] [CrossRef]
  16. Keit, E.; Coutu, B.; Zhen, W.; Zhang, C.; Lin, C.; Bennion, N.; Ganti, A.K.; Ernani, V.; Baine, M. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. Ann Transl Med 2021, 9, 227. [Google Scholar] [CrossRef]
  17. Vedel-Krogh, S.; Nielsen, S.F.; Nordestgaard, B.G. Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease. PLoS One 2015, 10, e0140571. [Google Scholar] [CrossRef]
  18. Kreuter, M.; Bonella, F.; Maher, T.M.; Costabel, U.; Spagnolo, P.; Weycker, D.; Kirchgaessler, K.U.; Kolb, M. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017, 72, 148–153. [Google Scholar] [CrossRef]
  19. Alexeeff, S.E.; Litonjua, A.A.; Sparrow, D.; Vokonas, P.S.; Schwartz, J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007, 176, 742–747. [Google Scholar] [CrossRef]
  20. Hubbard, R.; Venn, A.; Lewis, S.; Britton, J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000, 161, 5–8. [Google Scholar] [CrossRef]
  21. Ozawa, Y.; Suda, T.; Naito, T.; Enomoto, N.; Hashimoto, D.; Fujisawa, T.; Nakamura, Y.; Inui, N.; Nakamura, H.; Chida, K. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009, 14, 723–728. [Google Scholar] [CrossRef] [PubMed]
  22. Kim, H.C.; Lee, S.; Song, J.W. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep 2021, 11, 8312. [Google Scholar] [CrossRef] [PubMed]
  23. Saha, A.; Dickinson, P.; Shrimali, R.K.; Salem, A.; Agarwal, S. Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review. Clin Oncol (R Coll Radiol) 2022, 34, e493–e504. [Google Scholar] [CrossRef]
  24. Tang, C.; Mistry, H.; Bayman, N.; Chan, C.; Cobben, D.; Faivre-Finn, C.; Harris, M.; Kennedy, J.; Pemberton, L.; Price, G. , et al. Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Radiother Oncol 2021, 160, 78–81. [Google Scholar] [CrossRef]
  25. Sato, T.; Watanabe, A.; Kondo, H.; Kanzaki, M.; Okubo, K.; Yokoi, K.; Matsumoto, K.; Marutsuka, T.; Shinohara, H.; Teramukai, S. , et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 2015, 149, 64–69, 70.e61-62. [Google Scholar] [CrossRef] [PubMed]
  26. Kinoshita, T.; Azuma, K.; Sasada, T.; Okamoto, M.; Hattori, S.; Imamura, Y.; Yamada, K.; Tajiri, M.; Yoshida, T.; Zaizen, Y. , et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 2012, 4, 477–482. [Google Scholar] [CrossRef]
  27. Yoo, T.K.; Park, S.H.; Do Han, K.; Chae, B.J. Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ. BMC Cancer 2021, 21, 735. [Google Scholar] [CrossRef]
  28. Jang, S.Y.; Cha, Y.; Yoo, J.I.; Yu, Y.T.; Kim, J.T.; Park, C.H.; Choy, W. Effect of Pneumonia on All-cause Mortality after Elderly Hip Fracture: a Korean Nationwide Cohort Study. J Korean Med Sci 2020, 35, e9. [Google Scholar] [CrossRef]
  29. Kim, H.J.; Hann, H.J.; Hong, S.N.; Kim, K.H.; Ahn, I.M.; Song, J.Y.; Lee, S.H.; Ahn, H.S. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis 2015, 21, 623–630. [Google Scholar] [CrossRef]
  30. Cardwell, C.R.; Mc Menamin, Ú.; Hughes, C.M.; Murray, L.J. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2015, 24, 833–841. [Google Scholar] [CrossRef]
  31. Chen, Y.; Li, X.; Zhang, R.; Xia, Y.; Shao, Z.; Mei, Z. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res 2019, 141, 357–365. [Google Scholar] [CrossRef] [PubMed]
  32. Nguyen, P.A.; Chang, C.C.; Galvin, C.J.; Wang, Y.C.; An, S.Y.; Huang, C.W.; Wang, Y.H.; Hsu, M.H.; Li, Y.J.; Yang, H.C. Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan. Cancer Sci 2020, 111, 2965–2973. [Google Scholar] [CrossRef] [PubMed]
  33. Fiala, O.; Pesek, M.; Finek, J.; Minarik, M.; Benesova, L.; Bortlicek, Z.; Topolcan, O. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumour Biol 2015, 36, 5801–5805. [Google Scholar] [CrossRef]
  34. Omori, M.; Okuma, Y.; Hakozaki, T.; Hosomi, Y. Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. Mol Clin Oncol 2019, 10, 137–143. [Google Scholar] [CrossRef]
  35. Lee, Y.; Lee, K.H.; Lee, G.K.; Lee, S.H.; Lim, K.Y.; Joo, J.; Go, Y.J.; Lee, J.S.; Han, J.Y. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Res Treat 2017, 49, 1001–1011. [Google Scholar] [CrossRef]
  36. Yoo, H.; Jeong, B.H.; Chung, M.J.; Lee, K.S.; Kwon, O.J.; Chung, M.P. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC pulmonary medicine 2019, 19, 149. [Google Scholar] [CrossRef] [PubMed]
  37. Abu Qubo, A.; Numan, J.; Snijder, J.; Padilla, M.; Austin, J.H.M.; Capaccione, K.M.; Pernia, M.; Bustamante, J.; O'Connor, T.; Salvatore, M.M. Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe (Sheff) 2022, 18, 220147. [Google Scholar] [CrossRef]
  38. Farjah, F.; Wood, D.E.; Mulligan, M.S.; Krishnadasan, B.; Heagerty, P.J.; Symons, R.G.; Flum, D.R. Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. J Thorac Cardiovasc Surg 2009, 137, 1415–1421. [Google Scholar] [CrossRef]
  39. Yano, M.; Sasaki, H.; Moriyama, S.; Hikosaka, Y.; Yokota, K.; Kobayashi, S.; Hara, M.; Fujii, Y. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg 2012, 14, 146–150. [Google Scholar] [CrossRef]
  40. Haasbeek, C.J.A.; Palma, D.; Visser, O.; Lagerwaard, F.J.; Slotman, B.; Senan, S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012, 23, 2743–2747. [Google Scholar] [CrossRef]
  41. Kim, H.; Pyo, H.; Noh, J.M.; Lee, W.; Park, B.; Park, H.Y.; Yoo, H. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol 2019, 14, 19. [Google Scholar] [CrossRef] [PubMed]
  42. Conte, P.; Ascierto, P.A.; Patelli, G.; Danesi, R.; Vanzulli, A.; Sandomenico, F.; Tarsia, P.; Cattelan, A.; Comes, A.; De Laurentiis, M. , et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 2022, 7, 100404. [Google Scholar] [CrossRef] [PubMed]
  43. Minegishi, Y.; Gemma, A.; Homma, S.; Kishi, K.; Azuma, A.; Ogura, T.; Hamada, N.; Taniguchi, H.; Hattori, N.; Nishioka, Y. , et al. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Res, 2020, 6.
  44. Miura, Y.; Saito, T.; Tanaka, T.; Takoi, H.; Yatagai, Y.; Inomata, M.; Nei, T.; Saito, Y.; Gemma, A.; Azuma, A. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig 2018, 56, 72–79. [Google Scholar] [CrossRef] [PubMed]
  45. Kreuter, M.; Costabel, U.; Richeldi, L.; Cottin, V.; Wijsenbeek, M.; Bonella, F.; Bendstrup, E.; Maher, T.M.; Wachtlin, D.; Stowasser, S. , et al. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration 2018, 95, 317–326. [Google Scholar] [CrossRef]
  46. Yao, H.W.; Mao, L.G.; Zhu, J.P. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 2006, 33, 793–797. [Google Scholar] [CrossRef]
  47. Lee, J.H.; Lee, D.S.; Kim, E.K.; Choe, K.H.; Oh, Y.M.; Shim, T.S.; Kim, S.E.; Lee, Y.S.; Lee, S.D. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005, 172, 987–993. [Google Scholar] [CrossRef]
  48. Johnson, B.A.; Iacono, A.T.; Zeevi, A.; McCurry, K.R.; Duncan, S.R. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167, 1271–1278. [Google Scholar] [CrossRef]
  49. Gibbs, J.B.; Oliff, A.; Kohl, N.E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77, 175–178. [Google Scholar] [CrossRef]
  50. Zhang, X.; Teng, Y.; Yang, F.; Wang, M.; Hong, X.; Ye, L.G.; Gao, Y.N.; Chen, G.Y. MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncol Rep 2015, 33, 2599–2605. [Google Scholar] [CrossRef]
  51. Gomes, M.; Teixeira, A.L.; Coelho, A.; Araújo, A.; Medeiros, R. The role of inflammation in lung cancer. Adv Exp Med Biol 2014, 816, 1–23. [Google Scholar]
  52. Wang, J.; Li, C.; Tao, H.; Cheng, Y.; Han, L.; Li, X.; Hu, Y. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. PLoS One 2013, 8, e77950. [Google Scholar] [CrossRef]
  53. Heukels, P.; Moor, C.C.; von der Thüsen, J.H.; Wijsenbeek, M.S.; Kool, M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med 2019, 147, 79–91. [Google Scholar] [CrossRef]
  54. Eberlein, M.; Heusinger-Ribeiro, J.; Goppelt-Struebe, M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001, 133, 1172–1180. [Google Scholar] [CrossRef]
  55. McGillicuddy, F.C.; O'Toole, D.; Hickey, J.A.; Gallagher, W.M.; Dawson, K.A.; Keenan, A.K. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol 2006, 44, 469–475. [Google Scholar] [CrossRef]
  56. Kim, J.W.; Barrett, K.; Loke, Y.; Wilson, A.M. The effect of statin therapy on disease-related outcomes in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Respir Med Res 2021, 80, 100792. [Google Scholar] [CrossRef]
  57. Vainshelboim, B.; Myers, J.; Oliveira, J.; Izhakian, S.; Unterman, A.; Kramer, M.R. Physiological Responses and Prognostic Value of Common Exercise Testing Modalities in Idiopathic Pulmonary Fibrosis. J Cardiopulm Rehabil Prev 2019, 39, 193–198. [Google Scholar] [CrossRef]
  58. Badenes-Bonet, D.; Rodó-Pin, A.; Castillo-Villegas, D.; Vicens-Zygmunt, V.; Bermudo, G.; Hernández-González, F.; Portillo, K.; Martínez-Llorens, J.; Chalela, R.; Caguana, O. , et al. Predictors and changes of physical activity in idiopathic pulmonary fibrosis. BMC pulmonary medicine 2022, 22, 340. [Google Scholar] [CrossRef]
  59. Dowman, L.; Hill, C.J.; May, A.; Holland, A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2021, 2, Cd006322. [Google Scholar] [CrossRef]
  60. Nolan, C.M.; Polgar, O.; Schofield, S.J.; Patel, S.; Barker, R.E.; Walsh, J.A.; Ingram, K.A.; George, P.M.; Molyneaux, P.L.; Maher, T.M. , et al. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study. Chest 2022, 161, 728–737. [Google Scholar] [CrossRef]
  61. Vainshelboim, B.; Oliveira, J.; Izhakian, S.; Unterman, A.; Kramer, M.R. Lifestyle Behaviors and Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Respiration 2018, 95, 27–34. [Google Scholar] [CrossRef]
  62. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A. , et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183, 788–824. [Google Scholar] [CrossRef]
  63. Dempsey, T.M.; Sangaralingham, L.R.; Yao, X.; Sanghavi, D.; Shah, N.D.; Limper, A.H. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019, 200, 168–174. [Google Scholar] [CrossRef]
  64. Ali, M.O. Pulmonary complications in diabetes mellitus. Mymensingh Med J 2014, 23, 603–605. [Google Scholar]
  65. Ehrlich, S.F.; Quesenberry, C.P., Jr.; Van Den Eeden, S.K.; Shan, J.; Ferrara, A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010, 33, 55–60. [Google Scholar] [CrossRef]
  66. Enomoto, T.; Usuki, J.; Azuma, A.; Nakagawa, T.; Kudoh, S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003, 123, 2007–2011. [Google Scholar] [CrossRef]
  67. Hyldgaard, C.; Hilberg, O.; Bendstrup, E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014, 108, 647–653. [Google Scholar] [CrossRef]
  68. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021, 44, S111–s124. [Google Scholar] [CrossRef]
  69. Rangarajan, S.; Bone, N.B.; Zmijewska, A.A.; Jiang, S.; Park, D.W.; Bernard, K.; Locy, M.L.; Ravi, S.; Deshane, J.; Mannon, R.B. , et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med 2018, 24, 1121–1127. [Google Scholar] [CrossRef]
  70. Gou, S.; Zhu, T.; Wang, W.; Xiao, M.; Wang, X.C.; Chen, Z.H. Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. Int Immunopharmacol 2014, 22, 498–504. [Google Scholar] [CrossRef]
Preprints 80038 g001
Figure 1. Kaplan-Meier plot displaying cumulative incidence of lung cancer development (A) and overall survival (B) in IPF patients with and without statin use. IPF; Idiopathic pulmonary fibrosis, K-M; Kaplan-Meier
Figure 1. Kaplan-Meier plot displaying cumulative incidence of lung cancer development (A) and overall survival (B) in IPF patients with and without statin use. IPF; Idiopathic pulmonary fibrosis, K-M; Kaplan-Meier
Preprints 80038 g001
Table 1. Demographic characteristics of study groups by statin use.
Table 1. Demographic characteristics of study groups by statin use.
Characteristics Statin use p-value
No (n = 5810) Yes (n = 3372)
Age at diagnosis of IPF 67.2 ± 11.2 64.0 ± 10.2 < 0.001
Sex < 0.001
 Male 3896 (67.1%) 2002 (59.4%)
 Female 1914 (32.9%) 1370 (40.6%)
BMI 23.0 ± 3.2 24.0 ± 3.1 < 0.001
Total cholesterol 184.2 ± 34.8 199.7 ± 42.6 < 0.0001
Blood pressure
 Systolic 125.2 ± 17.1 126.6 ± 16.8 < 0.0001
 Diastolic 76.3 ± 10.6 77.3 ± 10.8 < 0.0001
Smoking history 0.076
 Never 3409 (61.1%) 2016 (62.3%)
 Ex-smoker 1100 (19.7%) 574 (17.7%)
 Current smoker 1073 (19.2%) 644 (19.9%)
Smoking amount < 0.001
 Less than a half pack 258 (38.1%) 95 (25.7%)
 Half pack to less than one pack 312 (46.1%) 180 (48.8%)
 One pack to less than two packs 97 (14.3%) 86 (23.3%)
 More than two packs 10 (1.5%) 8 (2.2%)
Smoking duration 0.217
 Less than five years 43 (4.1%) 16 (2.9%)
 Five to nine years 41 (3.9%) 23 (4.2%)
 10 to 19 years 146 (13.9%) 66 (12.1%)
 20 to 29 years 187 (17.8%) 120 (22.1%)
 30 years or more 634 (60.3%) 319 (58.6%)
Drinking frequency 0.004
 None 2363 (70.0%) 1285 (69.3%)
 Less than once per month 311 (9.2%) 155 (8.4%)
 Once per month 347 (10.3%) 214 (11.5%)
 Once per week 147 (4.4%) 113 (6.1%)
 Daily 210 (6.2%) 86 (4.6%)
Drinking amount at a time 0.001
 One to two drinks 499 (50.1%) 241 (43%)
 Three to four drinks 369 (37.0%) 208 (37.1%)
 Five to six drinks 72 (7.2%) 71 (12.7%)
 Seven to nine drinks 57 (5.7%) 41 (7.3%)
Physical activity frequency < 0.0001
 None 2143 (63.9%) 1060 (57.5%)
 One to two days per week 582 (17.3%) 391 (21.2%)
 Three to four days per week 274 (8.2%) 171 (9.3%)
 Five to six days per week 72 (2.1%) 41 (2.2%)
 Seven days per week 284 (8.5%) 179 (9.7%)
Physical activity intensity
(per week)
 Vigorous 0.8 ± 1.7 0.9 ± 1.8 0.022
 Moderate 1.0 ± 1.9 1.2 ± 2.0 0.036
 Walk 2.5 ± 2.6 2.6 ± 2.6 0.156
Comorbidities
Liver disease 65 (1.9%) 45 (2.4%) 0.258
Hypertension 508 (14.7%) 353 (18.7%) < 0.0001
Cerebrovascular diseases 67 (1.9%) 19 (1.0%) 0.013
Heart disease 103 (3.0%) 79 (4.2%) 0.026
Diabetes 241 (7.0%) 158 (8.4%) 0.073
Other cancers 58 (1.7%) 19 (1.0%) 0.064
Data are presented as n (%) or mean ± SD. IPF; Idiopathic pulmonary fibrosis, BMI; Body mass index.
Table 2. Comparison of clinical outcomes in IPF patients with and without statin use.
Table 2. Comparison of clinical outcomes in IPF patients with and without statin use.
Statin non-user (n=5810) Stain user (n=3372) p-value
Lung cancer development in IPF patients
(n = 850) 534 (9.2%) 316 (9.4%) 0.803
Duration (days)
 Lung cancer development 2194.6 ± 1601.4 3361.0 ± 1331.2 < 0.0001
 IPF diagnosis to death 2413.9 ±1778.7 3741.8 ± 1443.1 < 0.0001
No. of deaths 3887 (66.9%) 1404 (41.6%) < 0.0001
Data are presented as n (%) or mean ± SD. IPF; Idiopathic pulmonary fibrosis.
Table 4. Cox proportional hazard regression analysis of the clinical variables affecting mortality in IPF patients.
Table 4. Cox proportional hazard regression analysis of the clinical variables affecting mortality in IPF patients.
aHR Lower .95 Upper .95 p-value
Statin use 0.4254 0.3919 0.4617 < 0.001
Sex – female 0.6668 0.6121 0.7264 < 0.001
Ages at first diagnosis of IPF 1.0714 1.0673 1.0756 < 0.001
BMI 1.0020 0.9902 1.0139 0.7414
Total cholesterol 1.0005 0.9996 1.0014 0.2637
Blood pressure
 Systolic 0.9996 0.9968 1.0024 0.7931
 Diastolic 0.9999 0.9954 1.0044 0.959
Smoking history (ex + current) 1.0580 1.0096 1.1087 0.0182
Drinking experiences 0.9884 0.9586 1.0190 0.453
Exercise frequency 0.9291 0.9028 0.9563 < 0.001
Comorbidities
 Liver diseases 0.9104 0.7143 1.1604 0.4482
 Hypertension 1.0847 0.9868 1.1924 0.0921
 Stroke 0.9767 0.7646 1.2477 0.8504
 Heart diseases 0.9949 0.8323 1.1891 0.9548
 Diabetes 0.7783 0.6885 0.8798 < 0.001
 Cancers 1.0853 0.8276 1.4233 0.5539
aHR; Adjusted hazard ratio, IPF; Idiopathic pulmonary fibrosis, BMI; Body mass index
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated